1. Academic Validation
  2. The Novel Atypical Dopamine Uptake Inhibitor (S)-CE-123 Partially Reverses the Effort-Related Effects of the Dopamine Depleting Agent Tetrabenazine and Increases Progressive Ratio Responding

The Novel Atypical Dopamine Uptake Inhibitor (S)-CE-123 Partially Reverses the Effort-Related Effects of the Dopamine Depleting Agent Tetrabenazine and Increases Progressive Ratio Responding

  • Front Pharmacol. 2019 Jun 28:10:682. doi: 10.3389/fphar.2019.00682.
Renee A Rotolo 1 Vladimir Dragacevic 2 Predrag Kalaba 2 Ernst Urban 2 Martin Zehl 3 Alexander Roller 4 Judith Wackerlig 2 Thierry Langer 2 Marco Pistis 5 Maria Antonietta De Luca 5 Francesca Caria 5 Rebecca Schwartz 1 Rose E Presby 1 Jen-Hau Yang 1 Shanna Samels 1 Merce Correa 1 6 Gert Lubec 7 John D Salamone 1
Affiliations

Affiliations

  • 1 Department of Psychological Sciences, University of Connecticut, Storrs, CT, United States.
  • 2 Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Vienna, Austria.
  • 3 Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria.
  • 4 X-ray Structure Analysis Centre, Faculty of Chemistry, University of Vienna, Vienna, Austria.
  • 5 Department of Biomedical Sciences, University of Cagliari, National Institute of Neuroscience (INN), Cagliari, Italy.
  • 6 Àrea de Psicobiologia, Universitat Jaume I, Castelló, Spain.
  • 7 Department of Neuroproteomics, Paracelsus Medical University, Salzburg, Austria.
Abstract

Animal studies of effort-based choice behavior are being used to model effort-related motivational dysfunctions in humans. With these procedures, Animals are offered a choice between high-effort instrumental actions leading to highly valued reinforcers vs. low effort/low reward options. Several previous studies have shown that dopamine (DA) uptake inhibitors, including GBR12909, lisdexamfetamine, methylphenidate, and PRX-14040, can reverse the effort-related effects of the vesicular monoamine transport blocker tetrabenazine, which inhibits DA storage. Because many drugs that block DA transport act as major stimulants that also release DA, and produce a number of undesirable side effects, there is a need to develop and characterize novel atypical DA transport inhibitors. (S)-CE-123 ((S)-5-((benzhydrylsulfinyl) methyl)thiazole) is a recently developed analog of modafinil with the biochemical characteristics of an atypical DA transport blocker. The present paper describes the enantioselective synthesis and initial chemical characterization of (S)-CE-123, as well as behavioral experiments involving effort-based choice and microdialysis studies of extracellular DA. Rats were assessed using the fixed ratio 5/chow feeding choice test. Tetrabenazine (1.0 mg/kg) shifted choice behavior, decreasing lever pressing and increasing chow intake. (S)-CE-123 was coadministered at doses ranging from 6.0 to 24.0 mg/kg, and the highest dose partially but significantly reversed the effects of tetrabenazine, although this dose had no effect on fixed ratio responding when administered alone. Additional experiments showed that (S)-CE-123 significantly increased lever pressing on a progressive ratio/chow feeding choice task and that the effective dose (24.0 mg/kg) increased extracellular DA in nucleus accumbens core. In summary, (S)-CE-123 has the behavioral and neurochemical profile of a compound that can block DA transport, reverse the effort-related effects of tetrabenazine, and increase selection of high-effort progressive ratio responding. This suggests that (S)-CE-123 or a similar compound could be useful as a treatment for effort-related motivational dysfunction in humans.

Keywords

anergia; depression; dopamine; fatigue; modafinil; motivation; synthesis; transport.

Figures
Products